TY - JOUR
T1 - Schizophrenia
T2 - From brain morphology to psychopathology
AU - Foster, Adriana
AU - Usman, Manzoor
AU - Stirewalt, Edna
AU - Buckley, Peter
N1 - Funding Information:
Dr. Foster has received honoraria and research support from Roche Diagnostics and an educational grant from AstraZeneca International. Dr. Buckley has received research grants from AstraZeneca International, Bristol-Myers Squibb, Eli Lilly and Co., Janssen Pharmaceutica, the National Institute of Mental Health, Pfizer, Inc., Solvay Pharmaceuticals, Inc., and Wyeth; has served as a consultant for Abbott Laboratories, Alamo Pharmaceuticals, AstraZeneca International, Bristol-Myers Squibb, Eli Lilly and Co., Janssen Pharmaceutica, Pfizer, Inc., Merck & Co., Inc., Roche Diagnostics, Solvay Pharmaceuticals, Inc., and Wyeth; and has received honoraria and money for expenses from Abbott Laboratories, Alamo Pharmaceuticals, AstraZeneca International, Bristol-Myers Squibb, Eli Lilly and Co., Janssen Pharmaceutica, and Pfizer, Inc.
PY - 2007/8
Y1 - 2007/8
N2 - Ten years ago, Velakoulis, the author of a study cited the present article, was appreciating that the role of functional imaging in schizophrenia research would involve collaboration of clinicians, imaging specialists, and neuropsychologists, and the past year's literature proves his point. Our review shows that structural and functional imaging in schizophrenia is still alive and well. In the past year, it has focused on changes in "at-risk" and first-episode schizophrenia populations and has been used by researchers to characterize phenotypes of patients with schizophrenia prior to including them in genetic research. A decade ago, O'Donovan and Owen were cautiously optimistic about future advances in finding susceptibility genes for schizophrenia, and this year's literature, including their review, proves that the massive efforts of research in the genetics of schizophrenia have started to pay off. An almost-obscure area 10 years ago, pharmacogenetics of schizophrenia is well represented in the past year and gives hope to the practicing clinicians who are eagerly waiting to understand patients' variability in antipsychotic drug response. These and additional areas are included in our review of schizophrenia literature in the past year.
AB - Ten years ago, Velakoulis, the author of a study cited the present article, was appreciating that the role of functional imaging in schizophrenia research would involve collaboration of clinicians, imaging specialists, and neuropsychologists, and the past year's literature proves his point. Our review shows that structural and functional imaging in schizophrenia is still alive and well. In the past year, it has focused on changes in "at-risk" and first-episode schizophrenia populations and has been used by researchers to characterize phenotypes of patients with schizophrenia prior to including them in genetic research. A decade ago, O'Donovan and Owen were cautiously optimistic about future advances in finding susceptibility genes for schizophrenia, and this year's literature, including their review, proves that the massive efforts of research in the genetics of schizophrenia have started to pay off. An almost-obscure area 10 years ago, pharmacogenetics of schizophrenia is well represented in the past year and gives hope to the practicing clinicians who are eagerly waiting to understand patients' variability in antipsychotic drug response. These and additional areas are included in our review of schizophrenia literature in the past year.
UR - http://www.scopus.com/inward/record.url?scp=34848886607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848886607&partnerID=8YFLogxK
U2 - 10.1007/s11920-007-0042-6
DO - 10.1007/s11920-007-0042-6
M3 - Review article
C2 - 17880867
AN - SCOPUS:34848886607
SN - 1523-3812
VL - 9
SP - 337
EP - 342
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
IS - 4
ER -